Assessment of plasma dexamethasone levels after 1‐mg dexamethasone suppression test in adults with obesity
Authors' conclusion
Our results suggest that obesity does not affect plasma dexamethasone levels. However, dexamethasone measurement may still be helpful in patients who are being investigated for Cushing's syndrome and suspected to have a false-positive DST.
Study context
- Population
- Healthy obese and optimal-weight adults undergoing a standard overnight 1-mg dexamethasone suppression test
- Participants
- 62 vs 30
- Exposure
- Obese vs optimal-weight participants
- Obesen = 62
- Optimal-weightn = 30reference
- Outcome
- Plasma dexamethasone levels (LC-MS/MS) after 1-mg dexamethasone suppression test
Main finding
As reported in the abstract
Plasma dexamethasone level
P = 0.09
Observational data: associations, not effects.
Further findings
Correlation of sex, BMI, body surface area with plasma dexamethasone
- No correlations between sex, BMI, body surface area and plasma dexamethasone levels
Plasma dexamethasone >3.3 nmol/L, obesity class 1 vs class 2 vs optimal-weight
- No significant difference in proportion achieving plasma dexamethasone >3.3 nmol/L between obesity class 1, class 2 and optimal-weight
Original publication
Assessment of plasma dexamethasone levels after 1‐mg dexamethasone suppression test in adults with obesity. Clin Endocrinol (Oxf). Published 16 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →